Report center

西南证券-医药生物行业创新药专题：多发性骨髓瘤，BCMA靶向疗法推向前线-240604

多发性骨髓瘤全球年新发患者超30万人，达雷妥尤单抗引领一线治疗格局变化。据WHO，2022年全球新发多发性骨髓癌超30万例，我国新发多发性骨髓癌患者超3万例，是第二大血液癌症。目前硼替佐米、来那度胺和地塞米松（VRd）是中国NDMM的主流方案，NCCN指南进一步推荐了卡非佐米、来那度胺和地塞米松（KRd）方案，以CD38单抗为核心的联合疗法正在引领一线治疗格局变化。百亿美元市场以达雷妥尤单抗、来

No subject companies

Publishers

西南证券 View content →

Suggested next hops

Ranked by edge type and evidence strength (max 5). Prefer these over scrolling the full lists.

1西南证券Published by or linked to this institution1

Ask about this report neighborhood Read full report →

No related industries

No related reports

← Back to knowledge graph